Stereospecific transport of D-glucose into muscle and adipose tissue is the rate limiting step of glucose utilization in mammals. This transport process is tightly regulated by insulin and counterregulatory factors such as catecholamines and glucagon. For the study of glucose transport regulation, the ideal model is the isolated adipocyte because of the large effect of insulin, the homogeneity of the cell preparation, and the relative ease of the procedures to obtain well-defined membrane fractions which retain a large effect of insulin [1] [2] [3] . Muscle tissue, in contrast, does not offer these advantages. Thus, the majority of studies on insulin action has been performed in adipocytes. This review will, therefore, focus mainly on findings obtained with fat cells. However, the crucial findings, such as the translocation of transporters in response to insulin and the counterregulatory effect of catecholamines, have been confirmed in studies with muscle tissue which will be discussed briefly.
The mechanism of insulin action

The translocation mechanism
The stimulatory effect of insulin on glucose transport in the adipocyte persists after homogenization of cells and can be demonstrated in an isolated plasma membrane preparation [4] . This so-called fossil effect has facilitated the study of insulin action and has ultimately provided the crucial finding that adipocytes contain a large intracellular pool of glucose transporters from which transporters are translocated to the plasma membrane when cells are exposed to insulin [5] [6] [7] [8] [9] . Thus, it was concluded that an increase in the concentration of transporters in the plasma membrane accounts for the stimulatory effect of insulin on the transport activity. Similar findings have been obtained in muscle [10] , indicating that insulin-induced translocation of glucose transporters is common to insulin-sensitive tissue. Several other proteins are translocated in response to insulin, e.g. the insulin-like growth :factor II/mannose-6-phosphate receptor [11] and the transferrin receptor [12] . Comprehensive reviews on the translocation process have been published previously [13] [14] [15] .
The structure of the glucose transporter
The first primary sequence of a glucose transporter protein was established by analysis of a clonal cDNA from a human hepatoma cell line, the HepG2 cell [16] . Later, a cDNA with 97.6% homology was isolated from rat brain [17] . Expression of the protein in Escherichia coli induced a stereospecific glucose transport activity [18] . It was first believed that this transporter sequence, the HepG2 cell/erythrocyte/brain glucose transporter (GT/), is highly conserved, since mRNA hybridizing with the cDNA under stringent conditions was found in most tissues [17, 19] . However, screening a variety of tissues under less stringent conditions has led to the identification of other cDNAs encoding transporter-like proteins from liver [20] (liver glucose transporter, GT2), and from muscle [20] [21] [22] , adipose tissue [23] and differentiated 3T3-L1 cells [24] (muscle/adipose tissue glucose transporter, GT3). Thus, a family of glucose transport proteins exists, and most tissues appear to express more than one type of transporter.
The possible existence of a transporter unique to insulin-sensitive tissues was first demonstrated with a monoclonal antibody generated from a transporter preparation from adipocytes [25] . The subsequent cloning experiments verified the unique sequence [20] [21] [22] [23] [24] , and further raised the question whether insulin sensitivity of a cell is conferred by the amino acid sequence of its glucose transporter, its post-translational processing, and/or by an unknown ability of the cellular machinery. Previous data suggest that other constitutive transport proteins present in an insulin-responsive cell may respond to the hormone. In addition to GT3, the tissue specific glucose transporter, adipocytes express the transporter protein GT1. This protein was detected . Thus, the data indicate that at least two transporters (GT1 and GT3) are translocated in response to insulin. Therefore, if the primary structure confers insulin sensitivity of muscle and adipose tissue, the important structural regions must be homologous to GT1 and GT3. In the future, transfection studies in concert with specific peptide-derived antibodies will help to elucidate the relative contribution of the different transporters to the overall effect of insulin. In addition, site-directed mutagenesis and construction of chimeras will define the particular domains interacting with the translocating elements in the machinery of an insulin-responsive cell.
Changes of the transporter intrinsic activity by insulin
In spite of the substantial evidence that insulin triggers the insertion of intracellularly stored glucose transporters into the plasma membrane, two lines of evidence suggest that an additional activation of the glucose transporter might contribute to the effect of the hormone. Firstly, the quantitative comparison of transport activity and number of transporters in basal and insulin-stimulated cells and membrane fractions revealed that translocation cannot account for all of the effect of insulin in the adipocyte [30] . Secondly, in addition to the augmentation of transporters in the plasma membrane, the hormone produces several qualitative alterations of the glucose transporter [30, [33] [34] [35] [36] . Only a portion of the effect of insulin appears to be retained in membranes from cells exhibiting a large response to the hormone. In cells, insulin can stimulate the transport rate up to 30-fold, whereas, the largest response in plasma membranes reported so far is a 15-fold stimulation of transport activity [30] . Thus, insulin appears to activate either the translocated glucose transporters or carriers constitutively residing in the plasma membrane.
Recently, an elegant method has been described which labels glucose transporters in plasma membranes of 3T3-L1 adipocytes by oxidation and subsequent tritiation of galactose residues [31] . With this method, it was possible to more directly compare transport activity with transporter concentration, and again a significant discrepancy was found. Unfortunately, this study and others which have quantitated the transporter by techniques dependent on antisera have used sera specific for the GT1 and thus, have looked at only a portion of the total glucose transporters. The conclusions of these studies must be reconsidered after the relative numbers and the activity of each of the transporter species is known.
A decrease in the transport Km has recently been reported in highly insulin-responsive adipocytes [33] [34] . In other studies, however, the Km of glucose transport in basal and insulin-stimulated cells was indistinguishable [2, 30, 37, 38] . The divergent reports can be reconciled with the assumption that the incubation conditions, mainly the pattern of cell agitation and the cell concentration, determine whether an effect of insulin on transport Km is observed or not. If cells were moderately agitated (shaking at 40 cycles/min) and a cell concentration of approximately 2 • 106/ml was not exceeded, no change in the transport Km was detected either in cells or in plasma membranes prepared from these cells [30] . It appears quite possible that a higher cell concentration and incubation without any agitation gives rise to the accumulation of metabolites which increase the transport K~. The effect of insulin would then be a reversal of this effect. Nevertheless, the effect of the hormone on the transport Km confirms that insulin may change tran,;porter function as well as their number.
Insulin
Cat echol ami nes The temperature dependence of glucose transport activity in membranes from basal cells differs from that in membranes prepared from insulin-treated cells [30] . Consequently, the relative response to insulin as assayed in the membranes increases with the temperature (15-fold at 37~ as compared to 10-fold at 20~
Recently it was reported in a preliminary study that the activity of reconstituted glucose transporters was reduced by guanine nucleotides provided that cells were treated with insulin prior to isolation of membrane fractions [35, 36] . It was concluded that insulin had rendered the transporter sensitive to guanine nucleotides. Taken together, these findings suggest that the effect of insulin on the glucose transporter is not limited to a simple augmentation of its number in the plasma membrane, but comprises an array of functional changes.
Signal transduction via the receptor tyrosine kinase and a phosphorylation cascade
The action of insulin is initiated by binding to a specific membrane receptor [for a recent review see ref. 39]. This receptor has an intrinsic protein kinase activity localized in the [3-subunit which stimulates its autophosphorylation on tyrosine residues [40] . Activation of the receptor kinase is the most rapid event following binding of insulin to the receptor [41] and may be the unique signalling mechanism for all actions of insulin. It is beyond the scope of this review to comprehensively present the evidence in favour of such a signalling mechanism, but the crucial pieces of data linking the receptor kinase to glucose transport will be discussed briefly with some findings contradicting such a mechanism. Recently, site-directed insulin receptor mutants lacking the tyrosine phosphorylation sites [42] or the ATP-binding site [43] have been inserted into insulin-sensitive cells. In these cell lines, the effect of' insulin on 2-deoxyglucose transport was impaired in parallel to the inhibition of tyrosine kinase. Further, injection of a monoclonal antibody, which specifically inhibited the tyrosine kinase activity of the receptor, into Chinese hamster ovary cells inhibited the effect of insulin on 2-deoxyglucose transport, phosphorylation of ribosomal protein $6, and glycogen synthesis [44] . On the basis of these data, it can be concluded that the tyrosine kinase activation of the insulin receptor is required for the examined metabolic effects of insulin.
In contrast to these findings, other studies have dissociated tyrosine ldnase activation and glucose transport stimulation. A full insulinomimetic effect on glucose transport was observed in human adipocytes treated with a monoclonal antibody to the insulin receptor which antagonized the receptor kinase [45] . Furthermore, in isolated adipocytes only a minute portion of the maximal tyrosine kinase activity needs to be activated in order to produce full stimulation of glucose transport activity [46, 47] . Moreover, the finding that a covalenfly dimerized insulin derivative [48, 49] is a pure agonist in stimulating glucose transport but a partial agonist of the tyrosine kinase may indicate that different receptors are responsible for the two processes. Finally, insulin-like growth factor II stimulates a large increase in glucose transport activity in 3T3-L1 adipocytes probably via its own receptor [50] which does not possess a tyrosine kinase domain [51] .
After receptor occupation and autophosphorylation, several uncharacterized proteins in plasma membranes, intracellular microsomes, and cytosol are phosphorylated on tyrosine residues [52] [53] [54] [55] . These findings have supported the hypothesis that a phosphorylation cascade mediates and amplifies the intracellular action of insulin [56, 57] . However, the mechanism of signal transduction from the receptor-mediated tyrosine phosphorylation to the rapid changes in glucose metabolism is still not completely understood. Serine kinases appear to be involved, since insulin activates acetyl-CoA carboxylase by phosphorylation on serine residues [58] . Several insulin-dependent serine kinases have been found, and their activation through tyrosine phosphorylation has been suggested recently [59, 60] . Furthermore, some insulin-induced metabolic changes are mediated by dephosphorylation of enzymes, e.g. triglyceride lipase [61] and glycogen synthase [62] , requiring the activation of an insulin-dependent phosphatase. At present, it is unclear whether insulin changes the phosphorylation state of the transporter. Previous studies have failed to detect any phosphate incorporation into the transporter immunoprecipitated with antiserum against GT1 [63, 64] . In contrast, insulin was found to stimulate phosphate incorporation into the transporter detected by a monoclonal antibody against GT3 [65] . However, using the same antibody another group failed to observe this effect of insulin [66] . Interestingly, one of the insulin-dependent serine kinases phosphorylates the microtubule-associated protein MAP-2 [60] . It is tempting to speculate on a role of the microtubular system in mediating insulin dependent translocation of proteins.
Phosphorylation of the a-subunits of guanine nucleotide binding proteins (G-proteins) in response to insulin has been related to the phosphorylation cascade on the basis of the finding that the purified insulin receptor kinase phosphorylates the a-subunits of Gi, Go, and of transducin [67] [68] [69] . However, no phosphorylation of G-protein a-subunits was detected in immunoprecipitates from intact cells equilibrated with [32p]phosphate and treated with insulin [70, 71] . These data argue against a mediating role of phosphorylated G-protein a-subunits in insulin action.
In summary, there is little doubt that phosphorylation reactions, initiated by an insulin-dependent serine kinase, play a crucial role in the mechanism of signal transduction. As far as the role of the tyrosine kinase activity of the insulin receptor is concerned, some divergent findings still must be reconciled, and the presumed tyrosine phosphorylation of serine kinases has to be established unequivocally. The link between phosphorylation reactions and the translocation of glucose transporters is unclear; speculation might link the MAP-2 kinase [60] to these events.
Counterregulatory inhibition of glucose transport by catecholamines
Catecholamines reduce insulin-stimulated glucose transport activity in adipocytes provided that the inhibitory regulation of adenylate cyclase via Gi is not operafive [72] [73] [74] [75] . Conversely, antilipolytic agents e.g. adenosine reverse this effect, and produce a moderate augmentation of the insulin-stimulated transport activity [73, 76, 77] . Similar effects have been observed in skeletal muscle [78] . The inhibitory effect of catecholamines in adipocytes reflects both a shift of the concentration-response curve to higher insulin concentrations and a marked reduction of the maximal effect of insulin [15, 79] . As is discussed below, the first component may be attributed to inhibition of the insulin receptor kinase, whereas the latter effect appears to reflect a change in intrinsic activity of glucose transporters.
Inhibition of the insulin receptor tyrosine kinase activity
Several previous studies have suggested that catecholamines affect insulin receptor binding and/or function. When adipocytes incubated at a high cell concentration were exposed to isoproterenol, the affinity of insulin receptors was reduced [80, 81] . Similar data were obtained by stimulation of adenylate cyclase with the adenosine antagonist, theophylline [82] . Since the effect of the lipolytic agents was less pronounced when cells were incubated at lower cell concentrations, it appeared to be produced by a reduction of cellular ATP-levels [83, 84] due to intracellular accumulation of fatty acids or a drop in pH of the incubation medium [85] caused by the release of fatty acids. Under carefully controlled incubation conditions which prevent accumulation of fatty acids and keep the pH of the incubation medium constant, no change of receptor affinity but a moderate (20%) reduction of plasma membrane receptors was observed [79] . These receptors appeared to be internalized, since insulin binding in low-density microsomes was increased in response to the catecholamine. More importantly, catecholamines appear to also affect the tyrosine ldnase activity of the receptor. Again, the effect is much smaller under carefully controlled incubation conditions [79] than if cells are incubated at a high concentration [86] , but could account for the shift of the concentration-response curve to higher insulin concentrations. Total as well as tyrosine phosphorylation of the receptor 13-subunit is decreased [79] . Altogether, the data indicate that catecholamines impair insulin receptor kinase activity and thereby reduce insulin sensitivity of adipocytes.
Alteration of transporter activity by catecholamines
In addition to an inhibition of the insulin receptor kinase, a second mechanism which is unrelated to the translocation process is responsible for the effect of catecholamines on glucose transport [87] . Unlike that of insulin, the effect of catecholamines is rapidly reversed by cooling the cells to 22 ~ C and subsequent homogenization. The reversal can be blocked by addition of KCN to the cells prior to cooling and homogenization. With this procedure, plasma membranes can be prepared which exhibit a transport Vmax reduced by 40-60% without any change in the number of cytochalasin B binding sites due to the isoproterenol treatment. In addition, the affinity of the cytochalasin B binding site was significantly reduced, whereas the immunoreactivity of the plasma membrane glucose transporter was unchanged by the catecholamine [64] . These data led to the conclusion that catecholamines decrease the transporter intrinsic activity [87] . The opposite effect, an increase in the intrinsic activity of the transporter, appears to occur in response to adenylate cyclase inhibitors, since adenosine stimulates the transport activity in addition to counteracting the inhibitory effect of isoproterenol via Gi activation [77, 87] .
A comparison of changes in cAMP levels and activity of the cAMP-dependent kinase [77] revealed that these alterations can be dissociated from catecholamine-induced changes in transport activity. Thus, it was suggested that intrinsic activity changes of glucose transporters were not mediated by cAMP and the cAMP-dependent protein kinase but rather by a direct interaction of the transporter with guanine nucleotidebinding proteins. Consistent with this conclusion, no phosphorylation of the glucose transporter GT1 was observed in response to catecholamines [64] . In contrast, in a preliminary study, phosphorylation of GT3 was reported in response to isoproterenol [66] . On the other hand, other preliminary data indicate that guanine nucleotides can indeed inhibit glucose transport activity reconstituted from adipocyte membrane fractions [35, 36] in the absence of ATP; conditions unlikely to increase cAMP levels, A-kinase activity and the phosphorylation state of the transporter. Thus, further experiments are required to determine whether the intrinsic activity changes produced by catecholamines and adenosine reflect phosphorylation of the transporter or its interaction with G-proteins.
Effects of agents activating protein kinase C
Phorbol esters produce a stimulation of glucose transport in adipocytes [88] as well as in a muscle-like cell line [89] . This effect is probably mediated through protein kinase C, since other agents stimulating kinase C e.g. vasopressin produce similar effects [90] . In addition, phorbol esters stimulate phosphate incorporation into glucose transporters in adipocytes [64] . Like that of 835 insulin, the stimulatory effect of phorbol esters on glucose transport activity appears to be due to translocation of transporters. However, a striking discrepancy between the number of transporters and transport activity was observed in adipocytes after treatment with the phorbol esters [90, 91] . The stimulatory effect of the agents on transport activity approached only about 10% of that produced by insulin, but reflected a translocation of glucose transporters which was 50% of that in response to insulin [90] . Thus, it may been concluded that phorbol esters induce the translocation of inactive transporters.
Agents affecting transport activity by binding to the transporter
Forskolin
The diterpene forskolin is one of the most powerful stimulators of adenyllate cyclase [92] and has thus been widely used to characterize cAMP-dependent mechanisms [93] . However, several effects of forskolin have been described which appeared to occur independent of a stimulation of adenylate cyclase. Forskolin is a powerful inhibitor of glucose transport in erythrocytes, adipocytes and platelets, and it has been shown that the inhibitory effect of the diterpene reflects a direct interaction with the transporter [94] [95] [96] . A comparison of the relative potencies of forskolin and four forskolin derivatives in inhibiting glucose transport and stimulating adenylate cyclase was performed in rat adipocyte plasma membranes. This study revealed that forskolin initiates adenylate cyclase stimulation and glucose transport inhibition at different sites [97] . Recently, the photoreactive, iodinated forskolin derivative, 3 -iodo -4 -azidophenethylamido -7 -0 -succinyldeacetylforskolin, has been synthesized [98] . In erythrocytes, the photolabel covalently binds to an intrinsic membrane protein identified as the glucose transporter by its molecular weight and by tryptic peptide analysis [981. Furthermore, the compound specifically labelled a protein in adipocytes, tentatively identified as the glucose transporter (GT1 and/or GT3), which changes its cellular distribution in response to insulin [99, 100] .
Methylxanthines and inhibitors of nucleoside transport
Methylxanthines, e.g. theophylline, are potent inhibitors of glucose transport activity in adipocytes [83] . Since this effect could be dissociated from their effects on cAMP-levels, a direct interaction of the agents with the glucose transport, has been proposed [101] . Similarly, inhibitors of nucleoside transport (dipyridamole, nitrobenzylthioguanosine, nitrobenzylthioinosine and papaverine) are also potent inhibitors of glucose transport in rat adipocytes [102] . Moreover, these agents inhibit the specific binding of cytochalasin B to the glu-cose transporter [102] . Thus, glucose and nucleoside transporters appear to possess a similar site mediating an inhibitory regulation of their function. It is tempting to speculate that these sites, presumably located at the cytoplasmic surface of the membrane, are receptors for an endogenous ligand which adjusts the transport capacity of the cell to rapid changes of its metabolism.
Concluding remarks
Convincing evidence indicates that glucose transport activity in insulin-sensitive cells is regulated by translocation of intracellular transporters to the plasma membrane. In addition, the intrinsic activity of the transporter is regulated by insulin and catecholamines. Current research is focussed on the molecular basis of these changes, and circumstantial evidence suggests involvement of a guanine nucleotide-dependent mechanism, or a phosphorylation of the transporter. The signalling chain linking the insulin receptor to glucose transport activation is as yet not fully understood. It is reasonable to assume that a phosphorylation/dephosphorylation cascade mediates the metabolic effects of insulin. A currently debated question is whether the glucose transporter is phosphorylated in response to insulin. Alternatively, the phosphorylation of a protein associated with the intracellular vesicles containing the glucose transporters, or of a microtubule-associated protein, might be involved in the translocation process.
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